Cytosorbents Common Stock vs Capital Surpluse Analysis
CTSO Stock | USD 0.88 0.01 1.15% |
Cytosorbents Crp financial indicator trend analysis is way more than just evaluating Cytosorbents Crp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytosorbents Crp is a good investment. Please check the relationship between Cytosorbents Crp Common Stock and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.
Common Stock vs Capital Surpluse
Common Stock vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytosorbents Crp Common Stock account and Capital Surpluse. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Cytosorbents Crp's Common Stock and Capital Surpluse is -0.45. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Cytosorbents Crp, assuming nothing else is changed. The correlation between historical values of Cytosorbents Crp's Common Stock and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Cytosorbents Crp are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Common Stock i.e., Cytosorbents Crp's Common Stock and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | -0.45 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Common Stock
Capital Surpluse
Most indicators from Cytosorbents Crp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytosorbents Crp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.At this time, Cytosorbents Crp's Selling General Administrative is very stable compared to the past year. As of the 12th of December 2024, Issuance Of Capital Stock is likely to grow to about 17.5 M, while Tax Provision is likely to drop (854.4 K).
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 62.9M | 60.9M | 67.6M | 70.9M | Total Revenue | 40.1M | 29.4M | 36.3M | 38.2M |
Cytosorbents Crp fundamental ratios Correlations
Click cells to compare fundamentals
Cytosorbents Crp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cytosorbents Crp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.4M | 90.0M | 89.5M | 63.2M | 53.3M | 55.9M | |
Short Long Term Debt Total | 16.1M | 1.0M | 13.8M | 18.3M | 18.3M | 19.2M | |
Total Current Liabilities | 9.9M | 10.2M | 13.7M | 9.7M | 14.5M | 15.3M | |
Net Debt | 3.9M | (70.4M) | (38.3M) | (3.9M) | 4.2M | 4.4M | |
Retained Earnings | (188.8M) | (196.6M) | (221.2M) | (254.0M) | (282.5M) | (268.4M) | |
Cash | 12.2M | 71.4M | 52.1M | 22.1M | 14.1M | 13.2M | |
Common Stock Total Equity | 32.6K | 43.2K | 43.5K | 43.6K | 39.3K | 51.6K | |
Common Stock Shares Outstanding | 32.3M | 38.8M | 43.4M | 43.6M | 44.7M | 46.9M | |
Liabilities And Stockholders Equity | 27.4M | 90.0M | 89.5M | 63.2M | 53.3M | 55.9M | |
Total Liab | 24.0M | 10.7M | 26.9M | 27.9M | 30.0M | 31.5M | |
Property Plant And Equipment Gross | 3.0M | 3.1M | 18.6M | 23.3M | 25.2M | 26.4M | |
Total Current Assets | 20.9M | 82.5M | 64.3M | 33.8M | 25.7M | 17.6M | |
Accumulated Other Comprehensive Income | 526.0K | (1.7M) | 525.6K | 2.3M | 529.3K | 555.8K | |
Other Current Liab | 5.6M | 7.0M | 9.5M | 7.9M | 6.4M | 6.7M | |
Total Stockholder Equity | 3.4M | 79.2M | 62.6M | 35.4M | 23.3M | 12.9M | |
Property Plant And Equipment Net | 3.0M | 3.1M | 18.6M | 23.3M | 22.1M | 23.2M | |
Non Current Assets Total | 6.5M | 7.5M | 25.2M | 29.5M | 27.6M | 28.9M | |
Cash And Short Term Investments | 12.2M | 71.4M | 52.1M | 22.1M | 14.1M | 14.1M | |
Non Current Liabilities Total | 14.0M | 582K | 13.3M | 18.1M | 15.4M | 16.2M | |
Other Stockholder Equity | 191.6M | 277.5M | 283.2M | 287.0M | 305.2M | 160.4M | |
Common Stock | 32.6K | 43.2K | 43.5K | 43.6K | 54.2K | 53.5K | |
Accounts Payable | 2.0M | 1.8M | 2.8M | 1.7M | 3.8M | 4.0M | |
Non Currrent Assets Other | 3.5M | 4.3M | 1.9M | 1.7M | 1.5M | 1.2M | |
Other Current Assets | 2.1M | 3.2M | 2.9M | 5.0M | 1.8M | 1.2M | |
Good Will | 1.8M | 2.6M | 3.4M | 4.2M | 4.9M | 5.1M | |
Intangible Assets | 3.4M | 4.2M | 4.7M | 4.4M | 3.9M | 4.1M | |
Other Assets | 123.5K | 5.4M | 6.6M | 1.7M | 2.0M | 1.1M | |
Property Plant Equipment | 3.0M | 2.1M | 18.6M | 10.7M | 12.4M | 13.0M | |
Long Term Debt | 6.0M | 9.3M | 13.4M | 5M | 2.5M | 3.8M | |
Net Receivables | 4.5M | 5.2M | 4.5M | 5.7M | 6.1M | 6.4M | |
Retained Earnings Total Equity | (188.8M) | (196.6M) | (221.2M) | (254.0M) | (228.6M) | (217.2M) | |
Inventory | 2.1M | 2.7M | 4.8M | 3.5M | 3.7M | 1.9M | |
Short Term Debt | 2.1M | 447.5K | 570.6K | 108.9K | 2.9M | 3.0M | |
Net Tangible Assets | 56.6K | 79.2M | 62.6M | 35.4M | 40.7M | 23.3M | |
Capital Surpluse | 191.6M | 277.5M | 283.2M | 287.0M | 330.1M | 215.6M | |
Short Long Term Debt | 4M | 666.7K | 1.7M | 2.5M | 2.9M | 1.8M |
Pair Trading with Cytosorbents Crp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.Moving together with Cytosorbents Stock
0.63 | CI | Cigna Corp Downward Rally | PairCorr |
Moving against Cytosorbents Stock
0.79 | MD | Mednax Inc | PairCorr |
0.79 | ECOR | Electrocore LLC | PairCorr |
0.7 | VREX | Varex Imaging Corp | PairCorr |
0.58 | LH | Laboratory | PairCorr |
0.55 | DXCM | DexCom Inc | PairCorr |
The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.
The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.36) | Revenue Per Share 0.72 | Quarterly Revenue Growth 0.066 | Return On Assets (0.28) | Return On Equity (1.19) |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.